Order byBest matchMost fresh

FDA, COVID and vaccine

Digest more
Top News
Overview
Impacts
FDA tightens requirements for COVID vaccine, adding trials for healthy adults
The U.S. Food and Drug Administration on Tuesday said it plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under age 65, effectively limiting them to older adults and those at risk of developing severe illness.

Continue reading

Who can get updated COVID vaccines this fall? FDA will OK for high-risk groups, calls for new clinical trials
FDA offers new guidelines to shift COVID vaccine focus to high-risk groups
US FDA advisers to consider if new COVID shots should target LP.8.1 subvariant
The U.S. Senate plans to vote this week to bar California's landmark plan to end the sale of gasoline-only vehicles by 2035 that has been adopted by 11 other states, Majority Leader John Thune said on...

Continue reading

Annual COVID-19 Shots For Healthy Younger Adults, Children Will No Longer Be Routinely Approved
US regulators say annual COVID-19 shots for healthy younger adults and children will no longer be routinely approved
FDA sets new COVID booster guidelines for healthy adults under 65
Vaccine makers have argued that because COVID vaccines have been changed annually to match the circulating strain of the virus, new placebo-controlled trials could delay availability of the shots unt...

Continue reading

F.D.A. Poised to Restrict Access to Covid Vaccines
FDA to limit future Covid-19 shots to older people and those at risk of serious infection
Trump FDA overhauls COVID-19 vaccine approval to focus on older populations, high-risk individuals
The FDA announced a policy shift for COVID-19 vaccine approvals to focus on Americans considered high-risk of contracting the virus, and those older than age 65.
FDA sets new COVID booster guidelines for healthy adults under 65
The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.
Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker.
Nuvaxovid had been available under emergency use authorization but the full approval may allow it to better compete with rival vaccine makers.
Explore more
Feedback